FDA Request For Clarifying DSHEA, Like Mandatory Listing, Splits US Supplement Industry Groups
Already differing on supporting FDA suggestion for mandatory annual registration of each VMS product sold in US, consumer health industry stakeholders’ schism now extends to agency suggestion that Congress clarify its regulatory authority over supplement manufacturing and marketing.
You may also be interested in...
In report explaining congressional intent for omnibus spending bill, House and Senate appropriators note concerns about, and target $5m for, regulation of supplement market. Question on moving drug ingredients from Rx to nonprescription not accompanied by targeted funding.
Announcement of Senate confirmation of Robert Califf as commissioner came shortly after FDA announced recalls of products labeled as supplements but spiked with ED drugs. Like those and others recently identified as adulterated, supplements with undisclosed drugs were being found during Califf’s first stint in 2016 and 2017.
Filling in the blanks for which ingredients qualify for definition of hemp could be as difficult and complicated as the question of lawful use, says food and drug attorneys. A DEA rule from legislation de-scheduling hemp left room for confusion on which substances qualify.